265 related articles for article (PubMed ID: 15010369)
1. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
[TBL] [Abstract][Full Text] [Related]
2. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.
Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L
J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
[TBL] [Abstract][Full Text] [Related]
5. DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.
Dolman ME; van der Ploeg I; Koster J; Bate-Eya LT; Versteeg R; Caron HN; Molenaar JJ
PLoS One; 2015; 10(12):e0145744. PubMed ID: 26716839
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA-dependent protein kinase catalytic subunit by small molecule inhibitor NU7026 sensitizes human leukemic K562 cells to benzene metabolite-induced apoptosis.
You H; Kong MM; Wang LP; Xiao X; Liao HL; Bi ZY; Yan H; Wang H; Wang CH; Ma Q; Liu YQ; Bi YY
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):43-50. PubMed ID: 23392706
[TBL] [Abstract][Full Text] [Related]
7. DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines.
Sak A; Groneberg M; Stuschke M
Int J Radiat Biol; 2019 Sep; 95(9):1205-1219. PubMed ID: 31287365
[No Abstract] [Full Text] [Related]
8. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.
Deriano L; Guipaud O; Merle-Béral H; Binet JL; Ricoul M; Potocki-Veronese G; Favaudon V; Maciorowski Z; Muller C; Salles B; Sabatier L; Delic J
Blood; 2005 Jun; 105(12):4776-83. PubMed ID: 15718417
[TBL] [Abstract][Full Text] [Related]
9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
10. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
[TBL] [Abstract][Full Text] [Related]
12. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
13. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
15. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.
Kolb RH; Greer PM; Cao PT; Cowan KH; Yan Y
PLoS One; 2012; 7(11):e50281. PubMed ID: 23166842
[TBL] [Abstract][Full Text] [Related]
16. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
17. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
18. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Willmore E; Errington F; Tilby MJ; Austin CA
Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
[TBL] [Abstract][Full Text] [Related]
19. Activation of DNA damage repair pathways in response to nitrogen mustard-induced DNA damage and toxicity in skin keratinocytes.
Inturi S; Tewari-Singh N; Agarwal C; White CW; Agarwal R
Mutat Res; 2014; 763-764():53-63. PubMed ID: 24732344
[TBL] [Abstract][Full Text] [Related]
20. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
